 |
|
Drugs Associated With Bullous PemphigoidA Case-Control Study
Sylvie Bastuji-Garin, MD;
Pascal Joly, MD;
Catherine Picard-Dahan, MD;
Philippe Bernard, MD;
Loïc Vaillant, MD;
Christine Pauwels, MD;
Véronique Salagnac, MD;
Catherine Lok, MD;
Jean-Claude Roujeau, MD
Arch Dermatol. 1996;132(3):272-276.
Abstract
Background and Design
Bullous pemphigoid is the most frequent autoimmune blistering disease. It occurs in the elderly. The cause of this disease is unknown, but cases of bullous pemphigoid have been occasionally attributed to drug therapy. We conducted a multicenter prospective case-control study looking at the drugs used on a long-term basis before the onset of the disease in 116 incident cases of bullous pemphigoid and 216 control patients with malignant or benign skin tumors.
Results
Case patients and control patients received many drugs on a long-term basis (mean ± SD, 4.4±3.2 and 4.4±2.7 years, respectively). Two classes of drugs, neu-n roleptics and diuretics, were used more frequently by case patients than control patients. Neuroleptics were used by 15.5% of case patients and 8.3% of control patients (adjusted odds ratios, 1.9; 95% confidence interval, 0.95 to 3.8). Diuretics were used by 36.2% of case patients and 24.5% of control patients (adjusted odds ratios, 1.8; 95% confidence interval, 1.1 to 2.9). Among neuroleptics, no specific drug emerged. The association with diuretics was only linked to aldosterone antagonists, which were taken by 12.9% of case patients and 4.6% of control patients (adjusted odds ratios, 3.1; 95% confidence interval, 1.4 to 7.1).
Conclusions
These results suggest that some drug therapies may be a risk factor for bullous pemphigoid. The cause of this association should be further investigated.
(Arch Dermatol. 1996;132:272-276)
Author Affiliations
From the Department of Epidemiology and Public Health, Université Paris XII, Hôpital Henri-Mondor, Créteil (Dr Bastuji-Garin); and the Departments of Dermatology, Hôpital Charles Nicolle, Rouen (Dr Joly); Hôpital Bichat, Paris (Dr Picard-Dahan); Hôpital Dupuytren, Limoges (Dr Bernard); Hôpital Trousseau, Tours (Dr Vaillant); Hôpital de St Germain-en-Laye (Dr Pauwels); Hôpital Sébastopol, Reims (Dr Salagnac); Hôpital Sud, Amiens (Dr Lok); and Hôpital Henri-Mondor, Créteil (Dr Roujeau), France.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
Pasmatzi et al.
Diabetes Care 2011;34:e133-e133.
FULL TEXT
Anti-Bullous Pemphigoid 180 and 230 Antibodies in a Sample of Unaffected Subjects
Wieland et al.
Arch Dermatol 2010;146:21-25.
ABSTRACT
| FULL TEXT
Oral Terbinafine-Induced Bullous Pemphigoid
Aksakal et al.
The Annals of Pharmacotherapy 2003;37:1625-1627.
ABSTRACT
| FULL TEXT
Bullous Pemphigoid and Amyotrophic Lateral Sclerosis: A New Clue for Understanding the Bullous Disease?
Chosidow et al.
Arch Dermatol 2000;136:521-524.
ABSTRACT
| FULL TEXT
|
